For many, a visit to the dentist brings fear, anxiety, or memories of uncomfortable experiences. But dentistry is ...

In many genetic diseases, a small error in the DNA code can have devastating effects. These errors, called nonsense mutations ...

Dystrophin's isoforms are thought to contribute variably to neuropsychiatric disorders, behavioral disorders, and ...

Cardiac complications in Duchenne muscular dystrophy (DMD) are the result of cardiac muscle involvement that accompanies the ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further ...

Satellos CEO Frank Gleeson said: “Given the short 28-day treatment window ... of functional muscle tissue. There are some approved gene therapies for DMD, including Roche and Sarepta’s ...

Capricor's lead asset, deramiocel, targets DMD-related cardiomyopathy and faces ... This is in Phase 1 development. Then there are engineered exosomes for RNA, protein, and small molecule delivery.

There are some approved gene therapies for DMD ... Spain, the UK, and Japan), the DMD treatment market is expected to rise from sales of $2.3bn in 2023 to $5.2bn by 2033. This is mostly driven by ...

But DMD holds him back in ways we can’t control ... The hardest part is knowing that there’s a treatment available in places like America, Kuwait, and Brazil, yet we’re constantly up against the ...

In the U.S., ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in ...